• Managing syringe filling operations with effective containment strategies, isolator technologies, and dedicated product pathways
• Ensuring end-to-end CDMO capabilities to support injectable products transitioning from clinical to commercial scale
• Navigating increasing product complexity across formats, potencies, and markets without compromising execution speed
• Leveraging European manufacturing footprints and dual-site strategies to mitigate supply risk without added operational complexity
• Defining critical expectations early between sponsors and CDMOs to protect timelines, quality performance, and supply reliability